Paul Koller, M.D.

(877) 460-4673
Paul Koller, M.D.
Hematologist-Oncologist
Clinical Expertise
  • Leukemia
Research Area
  • Hematology and Hematopoietic Cell Transplantation
  • Leukemia
Academic Appointments
  • Assistant Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Leukemia
Acute Myeloid Leukemia

Dr. Paul Koller is an Assistant Professor in the Department of Hematology and Hematopoietic Cell Transplantation in the Division of Leukemia at City of Hope Comprehensive Cancer Center in Duarte, California. He is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute and chronic leukemia, including biologically rational targeted therapy and novel combination therapies. He is a primary investigator on numerous trials in chronic myeloid leukemia, acute myeloid leukemia, acute lymphoid leukemia, and high-risk myelodysplastic syndrome.

Location

Education & Experience

Board Certifications

  • 2018 American Board of Internal Medicine — Hematology
  • 2018 American Board of Internal Medicine — Medical Oncology
  • 2015 American Board of Internal Medicine — Internal Medicine

Degrees

  • 2012, M.D., Medicine, University of Texas, Houston, TX

Fellowship

  • 2015–2018, Hematology/Oncology Fellow, Supervisor: Robert Wolff, M.D., Department of Cancer Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX

Residency

  • 2012–2015, Internal Medicine, Supervisor: Richard Hamill, M.D., Department of Internal Medicine, Baylor College of Medicine Affiliated Hospitals, Houston, TX

Professional Experience

  • 2019–present, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California
  • 2018–2019, Instructor, Department of Leukemia, MD Anderson Cancer Center, Houston, TX

Awards & Memberships

Awards

  • 2018, Conquer Cancer Foundation of ASCO/Texas Society of Clinical Oncology Young Investigator Award
  • 2018, Top recipients of the 2018 TxSCO Fellows Research Competition

Publications

  • Salhotra A, Yang D, Al Malki MM, Mokhtari S, Knobler D, Agarwal V, Sandhu K, Park G, Aribi A, Ali H, Aldoss I, Otoukesh S, Arslan S, Ball B, Koller P, Amanam I, Pourhassan H, Blackmon A, Becker P, Pullarkat V, Artz AS, Smith E, Marcucci G, Forman S, Stein A, Nakamura R. Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis. Bone Marrow Transplant. 2026 Jan;61(1):82-91. doi: 10.1038/s41409-025-02738-4. Epub 2025 Nov 18. PMID: 41254192; PMCID: PMC12819140.
  • Otoukesh S, Amanam I, Yang D, Samuels D, Salhotra A, Artz A, Arslan S, Aldoss I, Sandhu K, Koller P, Aribi A, Curtin P, Stein A, Marcucci G, Al Malki M, Ali H, Rahmanuddin S, Nakamura R, Pullarkat V. Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis. Bone Marrow Transplant. 2025 Dec;60(12):1666-1668. doi: 10.1038/s41409-025-02724-w. Epub 2025 Sep 24. PMID: 40993219.
  • Tinajero J, Nguyen K, Ngo D, Agrawal V, Shan H, Zhang J, Koller P, Pourhassan H, Murphy L, Samara Y, Arslan S, Forman S, Stein A, Marcucci G, Pullarkat V, Aldoss I. The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden. Am J Hematol. 2025 Dec;100(12):2209-2219. doi: 10.1002/ajh.70057. Epub 2025 Sep 9. PMID: 40926515.
  • Tinajero J, Ngo D, Lee B, Kim H, Ball B, Koller P, Amanam I, Pourhassan H, Ali H, Otoukesh S, Salhotra A, Blackmon A, Sandhu K. FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience. J Oncol Pharm Pract. 2025 Nov 20:10781552251396885. doi: 10.1177/10781552251396885. Epub ahead of print. PMID: 41264473.
  • Pourhassan H, Tinajero J, Ma H, Jackson R, Pillai R, Ngo D, Agrawal V, Koller P, Ball B, Blackmon A, Salhotra A, Al Malki M, Aribi A, Otoukesh S, Artz A, Becker P, Nakamura R, Stein A, Forman S, Marcucci G, Pullarkat V, Aldoss I. The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia. Br J Haematol. 2025 Oct;207(4):1377-1387. doi: 10.1111/bjh.20260. Epub 2025 Sep 1. PMID: 40890465.
  • Othman T, Baird JH, Wang Y, Pak S, Zhong H, Aldoss I, Cai JL, Danilov A, Phillips TJ, Agrawal V, Sandhu KS, Mei M, Koller PB, Palmer J, Forman SJ, Budde LE, Aribi A. Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma. Am J Hematol. 2025 Oct;100(10):1916-1919. doi: 10.1002/ajh.70038. Epub 2025 Aug 20. PMID: 40833241.
  • Nguyen T, Markary T, Tsai NC, Tiemann K, Mokhtari S, Samara Y, Pourhassan H, Blackmon A, Arslan S, Otoukesh S, Agarwal V, Amanam I, Ball B, Koller P, Aribi A, Salhotra A, Sandhu K, Pullarkat V, Becker P, Aldoss I, Ali H, Stewart F, Smith E, Stein A, Marcucci G, Forman SJ, Artz A, Nakamura R, Al Malki MM. Outcomes after Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment. Transplant Cell Ther. 2025 Oct;31(10):824.e1-824.e13. doi: 10.1016/j.jtct.2025.07.001. Epub 2025 Jul 3. PMID: 40617293; PMCID: PMC12416212.
  • Tinajero J, Ngo D, Motta M, Agrawal V, Koller P, Pourhassan H, Murphy L, Arslan S, Forman S, Stein A, Marcucci G, Pullarkat V, Aldoss I. The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission. Br J Haematol. 2025 Aug;207(2):426-431. doi: 10.1111/bjh.20200. Epub 2025 Jun 10. PMID: 40492422.
  • Mehta P, Ngo D, Tinajero J, Agrawal V, Koller P, Pourhassan H, Arslan S, Stein A, Pullarkat V, Aldoss I. Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults ≥40 years old. Leuk Lymphoma. 2025 Oct;66(10):1937-1941. doi: 10.1080/10428194.2025.2506003. Epub 2025 May 21. PMID: 40395178.
  • Agrawal V, Koller P, Stein A, Pullarkat V, Aldoss I. The Role of Transplant for Philadelphia-positive B-cell Acute Lymphoblastic Leukemia in 2025. Curr Oncol Rep. 2025 Jun;27(6):748-760. doi: 10.1007/s11912-025-01683-1. Epub 2025 May 9. PMID: 40343686.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Recommend this provider office
5.0
Provider explain in way you understand
5.0
Provider listen carefully to you
5.0
Know important info medical history
5.0
Show respect for what you say
5.0
Spend enough time with you
4.9
Rate provider 0-10
03/30/26
Excellent - Verified patient
03/30/26
Excellent - Verified patient
03/21/26
He's the best - Verified patient
03/02/26
Dr. Koller, [...], and the entire team are amazing. The care I received throughout my treatment has been excellent. I'm very grateful for their professionalism, kindness, and support. Thank you. - Verified patient
01/28/26
Very knowledgeable, informative, and friendly - thanks - Verified patient